Viridian Therapeutics, Inc. (VRDN) — Financial statements
Income statement, balance sheet, and cash flow for Viridian Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 71↑23359.9% | 0.30↓3.8% | 0.31↓82.3% | 2↓40.2% | 3 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 71↑23359.9% | 0.30↓3.8% | 0.31↓82.3% | 2↓40.2% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 339↑42.3% | 238↑49.1% | 160↑58.3% | 101↑77.4% | 57 | |
| General & Administrative Expenses | 95↑56.0% | 61↓35.7% | 95↑170.0% | 35↑36.3% | 26 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 95↑56.0% | 61↓35.7% | 95↑170.0% | 35↑36.3% | 26 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 434↑45.1% | 299↑17.5% | 255↑87.2% | 136↑64.6% | 83 | |
| Total Costs & Expenses | 434↑45.1% | 299↑17.5% | 255↑87.2% | 136↑64.6% | 83 | |
| Operating Results | ||||||
| Operating Income | -363↓21.5% | -299↓17.5% | -254↓89.5% | -134↓68.5% | -80 | |
| Depreciation & Amortization | 0.46↓62.9% | 1↑137.5% | 0.52↑104.7% | 0.26↑112.5% | 0.12 | |
| EBITDA | -337↓26.9% | -266↓12.9% | -235↓82.3% | -129↓62.9% | -79 | |
| EBIT | -338↓26.5% | -267↓13.1% | -236↓82.3% | -129↓62.9% | -79 | |
| Interest & Other Income | ||||||
| Net Interest Income | 22↓22.8% | 29↑74.0% | 17↑277.3% | 4↑1306.3% | 0.32 | |
| Interest Income | 27↓14.7% | 32↑73.1% | 19↑277.6% | 5↑1445.9% | 0.32 | |
| Interest Expense | 5↑62.4% | 3↑64.9% | 2↑280.0% | 0.49↑16100.0% | 0.00 | |
| Non-Operating Income | -26↑19.9% | -32↓73.1% | -19↓277.6% | -5↓1445.9% | -0.32 | |
| Other Income / Expenses | 21↓28.5% | 29↑74.0% | 17↑277.3% | 4↑1306.3% | 0.32 | |
| Income Before Tax | -343↓26.9% | -270↓13.6% | -238↓83.0% | -130↓63.5% | -79 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -343↓26.9% | -270↓13.6% | -238↓83.0% | -130↓63.5% | -79 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -343↓26.9% | -270↓13.6% | -238↓83.0% | -130↓63.5% | -79 | |
| Bottom-Line Net Income | -282↓4.4% | -270↓13.6% | -238↓83.0% | -130↓63.5% | -79 | |
| EPS (Basic) | -3.32↑16.6% | -3.98↑25.0% | -5.31↓35.8% | -3.91↑41.3% | -6.66 | |
| EPS (Diluted) | -3.32↑16.6% | -3.98↑25.0% | -5.31↓35.8% | -3.91↑41.3% | -6.66 | |
| Weighted Average Shares | 85↑24.9% | 68↑51.7% | 45↑39.5% | 32↑169.2% | 12 | |
| Weighted Average Diluted Shares | 85↑24.9% | 68↑51.7% | 45↑39.5% | 32↑169.2% | 12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.